
The Zhitong Finance App learned that CITIC Securities released a research report saying that the national health insurance negotiations will continue to support innovative policy directions, and that the introduction of new varieties, expansion of indications, and hospital payment support will jointly drive commercial growth in 2027. On November 14, 2026, 107 new drugs were added to the new catalogue, including 51 Class 1 innovative drugs, and the quantity reached a new high. For the first time, CAR-T was included in basic medical insurance. This adjustment improves the link between pre-declaration and commercial insurance to basic medical insurance, further clarifies long-term renewal rules, and promotes “dual channel” supply of drugs into hospitals.
CITIC Securities's main views are as follows:
Entry and renewal rules have been further improved, and long-term commercialization expectations for innovative drugs have become more clear.
A pre-declaration mechanism was added in 2026, which allows pre-filling of drugs or indications that have completed technical review by June 10, and to submit approved materials before July 3; drugs on the commercial insurance catalogue can be declared for basic medical insurance, and 2 varieties have now been transferred. For exclusive drugs that have been continuously included in the negotiation catalogue for 8 years and the agreement expires in that year, the method for adjusting payment standards when switching to the regular catalogue has been further clarified. The bank believes that the integration of declarations and the improvement of price rules will help reduce mismatches in entry time and enhance the predictability of long-term business operations.
Hospital admission and payment facilities are progressing simultaneously, and attention is being paid to the transformation of catalogue entry into prescription volume.
New drugs must be listed online by the end of 2026. In principle, medical institutions will hold a pharmaceutical council meeting before the end of February 2027 to set up or open temporary procurement channels as needed; all regions will simultaneously update the “dual channel” and separate payment scope, and cases that are not suitable for payment according to disease type standards can be declared for special cases. The new version of the catalogue will be implemented on January 1, 2027. Reimbursement must comply with the instructions, limited scope of medical insurance payments, and local treatment policies. The above arrangement is expected to lower the medication threshold for patients and facilitate the transformation of new medical insurance coverage into actual usage.
In the publicly comparable sample, over 80% of expired and renewed drugs maintained their original prices, and the price reduction involved 14 drugs.
According to the 2025 and 2026 public payment standards, there are a total of 136 drugs and 187 records with the same name and the same specification that can be compared. Of these, 64 drugs have expired and been renewed; 52 have maintained their original prices, accounting for 81.3%; the original agreement for 70 drugs remains in effect, and the prices have not been adjusted; the remaining 2 agreements have not yet expired, but the prices have all been reduced. A total of 14 drugs have been reduced in price, of which 20 have been reduced in price. Of these, 12 drugs were renewed after expiration and 2 were adjusted during the agreement period.
According to the company's disclosure, Cinda Biotech introduced 4 products for the first time; 3 new indications (including cooperative promotion products) were added for the first time; 3 Chinese biopharmaceuticals were introduced for the first time, and 2 insured drugs added 6 new indications (including 1 authorized product); 3 models of Hengrui Pharmaceuticals were introduced for the first time, and 2 new indications were added to 2 insured drugs. One product of Collenbotai was introduced for the first time, and 2 new indications were added to 1 of the covered drugs; Rongchang Biotech Taitacip pre-filled needles were introduced for the first time, and 2 additional indications for the insured drug were added. New varieties and expanded indications for existing products are expected to jointly support domestic sales growth of related enterprises in 2027.
CAR-T is covered by basic medical insurance for the first time, and the accessibility of cell therapy is expected to improve.
Yao Ming Ju Norique Orense became the first CAR-T product to be included in basic medical insurance, providing new treatment opportunities for patients who were previously limited in their ability to pay. This time, a total of 2 types from the original commercial insurance catalogue were transferred to basic medical insurance, and support policies related to the original commercial insurance catalogue were still applied for 4 years after the transfer, further clarifying the path of linking high-value innovative drugs from commercial insurance to basic medical insurance. The bank believes that this change is expected to increase the penetration rate of CAR-T treatment in the country. Keji Pharmaceutical CT041 is now included in the commercial insurance innovative drug catalogue.
The expansion of the scope of ADC medical insurance payments to more advanced treatment lines and more cancer types is expected to drive domestic sales growth.
Colombotel SAC-TMT added EGFR mutant non-squamous nsCLC indications that progressed after EGFR-TKI treatment, which moved forward from the original “EGFR-TKI and platinum-containing chemotherapy”; at the same time, HR+/HER2-breast cancer that underwent endocrine treatment and had received at least first-line chemotherapy at an advanced stage was added. Hengrui Pharmaceutical's Ruikang trastuzumab added locally advanced or metastatic HER2-positive breast cancer that has previously been treated with at least one anti-HER2 drug to the original HER2 mutation NSCLC payment scope. In terms of new varieties, Collenbotai HER2 ADC Bodutrastuzumab was included in medical insurance for the first time, covering advanced HER2-positive breast cancer treated with anti-HER2; Bailitian Henglunconitumab was included in medical insurance in the year it was marketed, covering at least previous second-line systemic chemotherapy and recurrent or metastatic nasopharyngeal cancer where PD- (L) 1 treatment failed. The bank believes that the introduction of new products and the expansion of indications for existing products will jointly expand the population covered by ADC medical insurance. With the implementation of hospital equipment and prescriptions, it is expected to increase domestic sales in 2027.
Immunity, metabolism, and new types of hematoma are included in medical insurance to expand the number of new patients.
Rongchang Biotech added payment coverage for active dry syndrome and primary IgA nephropathy at risk of progression to further expand disease coverage. Cinda Biotech was introduced for the first time as an indication for type 2 diabetes in adults. Pikonqibimab simultaneously covered moderate to severe plaque psoriasis; Mashidu peptide weight loss indications were not reimbursed by basic medical insurance as a result. In the field of hematoma, BeiGene Sotocla and Yasheng Pharmaceutical's lisatocla are all included in the CLL/SLL payment scope after treatment with BTK inhibitors. Sotocla also covers R/R MCL patients who meet previous treatment requirements, which is expected to promote commercialization of domestically produced BCL-2 inhibitors.
Medical insurance coverage of the joint immunization program has been expanded, and renewal prices for some dual-antibody varieties have remained stable.
The Chinese biopharmaceutical bemosubizumab was included in medical insurance for the first time and covered 5 indications, and coumoxil was also included for the first time; anlotinib and pimiprizumab added 5 new medical insurance payment indications and 1, respectively, to promote joint programs such as “Defu Combination” and “Double An Combination” to cover more patients. Fuhong Hanlinslulizumab was included in medical insurance for the first time, covering all 5 approved indications. Kangfang Biotech's Evosi and Cardonil continued the original medical insurance payment coverage. The bank believes that the inclusion of new products and the expansion of joint programs are expected to expand patient coverage and drive sales growth.
Risk warning:
The risk that the progress of new drug development falls short of expectations or failure; the risk that the approval process of the new drug falls short of expectations; the risk that the efficacy and safety of the new drug falls short of expectations after marketing; the risk of product commercialization falling short of expectations and the risk of unfavorable sales; the risk of changes in the market competition pattern; the risk of changes in pharmaceutical policies exceeding expectations, and the risk of insufficient scope of intellectual property protection.